Figure 2.
Improved metabolic parameters in MKO mice fed an HFD. (A) Body weight evolution of male Ctrl and MKO mice fed an HFD for 6 wk (n = 8 per group). (B) Fasting glucose, fasting insulin, and homeostatic model assessment-insulin resistance in male Ctrl and MKO mice fed an HFD for 6 wk (n = 5–6 per group). IPGTT (C) and IPITT (D) in male Ctrl and MKO mice fed an HFD for 6 wk (n = 6 per group). (E) Hyperinsulinemic–euglycemic clamp. Glucose uptake, glucose infusion rate (GIR) and hepatic glucose production (HGP) in male Ctrl and MKO mice fed an HFD for 6 wk (n = 5 per group). (F) Energy expenditure (EE) adjusted for body mass by ANOVA in 8-wk-old male Ctrl and MKO mice fed an HFD for 1 wk (n = 5 per group). (G) hematoxylin and eosin (H&E) and oil red O staining of liver (left) and eWAT (right) in male Ctrl and MKO mice fed an HFD for 6 wk (n = 5 per group). Bar, 100 µm. (H–J) Relative expression of genes related to β-oxidation (Ppara, Acadl, Acadm, Pgc1a, and Cpt1a/b), mitochondria (Cox1 and Ndufa9), and lipid metabolism (Hsl and Atgl, lipolysis; Fasn and Pparg, lipogenesis) in eWAT (H), liver (I), and EDL (J) in Ctrl and MKO mice fed an HFD for 6 wk (n = 5 per group). Plasma free fatty acid (K) and glycerol (L) concentrations in HFD-fed male Ctrl and MKO mice (n = 5 per group). (M) Ex vivo fatty acid oxidation (FAO) of infused 1-14C-palmitate in eWAT, liver, BAT, and EDL of HFD-fed Ctrl and MKO mice (n = 5 per group). All data represent mean ± SEM. *, P < 0.05; **, P < 0.01.